The reduction of pro-inflammatory cytokines, improvement in intestinal barrier integrity, and potential modulation of gut microbiota composition represent mechanisms that could theoretically complement existing IBD therapies
Most patients experience peak nausea during the first 24 weeks and the 12 days following their weekly injection
Most compounded tirzepatide formulations remain stable for 2448 hours at room temperature (6877F)
Eligibility generally depends on your medical history, BMI, and clinical assessment by the physician during your consultation
This medication can also be appealing to patients looking for the convenience of a once weekly injection
Behavioral Tracking: Monitor factors influencing weight loss, such as eating triggers, emotional episodes, stress levels, and sleep patterns